Remove our-products
article thumbnail

STAT+: FDA approves Medtronic high blood pressure device despite a negative advisory panel vote

STAT

The FDA approved a similar product, part of a device class called renal denervation, from startup Recor Medical earlier this month. “We partnered closely with leading experts in our clinical community who could help us in our journey to get this technology to the people who need it most.

339
339
article thumbnail

STAT+: A spending frenzy on obesity drugs

STAT

  Sign up  to get our biotech newsletter in your inbox. Novo’s move to pull an insulin highlights a policy gap About a year ago, Novo Nordisk announced that it would cut the price of several insulin products by up to 75%. Want to stay on top of the science and politics driving biotech today?  Good morning!

Diabetes 297
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Psychedelic investment continues to ramp up

STAT

  Sign up  to get our biotech newsletter in your inbox. Today, we talk about psychedelics, obesity, and production issues with generic drugs. Want to stay on top of the science and politics driving biotech today?  Hope your team of choice was victorious in last night’s sports ball match.

article thumbnail

Morning Rounds: Why health care costs are nearly a fifth of the GDP

STAT

Sign up for our Morning Rounds newsletter  here. Don’t miss Nicholas Florko’s jaw-dropping investigation into medical marijuana businesses marketing their products for cancer or depression with no regulatory oversight. Understand how science, health policy, and medicine shape the world everyday. Good morning.

article thumbnail

STAT+: Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro

STAT

In a statement , Lilly maintained it “cannot validate the safety or effectiveness of products claiming to contain tirzepatide (the active ingredient in Mounjaro) that are not our own branded product… Entities should be stopped from providing drug products in violation of consumer protection laws, particularly where they promise their (..)

article thumbnail

STAT+: FDA’s Peter Marks seems inclined to grant full approval to Sarepta’s Duchenne gene therapy

STAT

“Hypothetically, if you had a product that used an aggregate scale and all of the components of that aggregate scale looked pretty good, or nearly all of them look pretty good, but the aggregate, for various reasons, didn’t come out perfectly. We approved products based on that,” Marks told me.

356
356
article thumbnail

STAT+: How doctors and nurses shape Google’s AI, DEA extends telehealth flexibilities

STAT

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how tech is transforming the life sciences.  “It doesn’t really help if I come and just give random advice about pulmonology…I have to know the product constraints, the technical constraints and the business constraints.”

255
255